- Home
- NGNE vs SOPH Comparison
NGNE vs SOPH Comparison
Compare NGNE & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NGNE | SOPH |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.8M | 330.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NGNE | SOPH |
|---|---|---|
| Price | $21.31 | $4.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $38.50 | $7.00 |
| AVG Volume (30 Days) | ★ 226.2K | 100.5K |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $73,297,000.00 |
| Revenue This Year | N/A | $18.32 |
| Revenue Next Year | N/A | $15.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.66 |
| 52 Week Low | $6.88 | $2.58 |
| 52 Week High | $37.27 | $5.30 |
Technical Indicators
Market Signals| Indicator | NGNE | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 44.24 | 50.75 |
| Support Level | $19.65 | $4.54 |
| Resistance Level | $23.00 | $4.84 |
| Average True Range (ATR) | 1.44 | 0.30 |
| MACD | 0.27 | -0.03 |
| Stochastic Oscillator | 50.79 | 33.33 |
Price Performance
Historical ComparisonAbout NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.